Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CHKA
REST API REST API
Homo sapiens
CHKA is differentially expressed in 281 experiments: 139 organism parts: testis, hypothalamus, ... (137 more);, 203 disease states: normal, prostate carcinoma, ... (201 more);, 104 cell types 455 cell lines 41 compound treatments and 75 other conditions.
Synonyms CKI, CHK
Orthologs CKI1 (Saccharomyces cerevisiae)   Chka (Rattus norvegicus)   CHKA (Bos taurus)   Chka (Mus musculus)   CHKA (Gallus gallus)   chka (Danio rerio)   ENSCING00000007566 (Ciona intestinalis)   EKI1 (Saccharomyces cerevisiae)   chka (Xenopus laevis)   CHKA (Canis familiaris)   CG2201 (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term lipid transport, choline kinase activity, phospholipid biosynthetic process, phosphotransferase activity, alcohol group as acceptor, cytoplasm, signal transducer activity, ATP binding, lipid metabolic process, nucleotide binding, ethanolamine kinase activity, phosphatidylcholine biosynthetic process, signal transduction, choline metabolic process, drug binding, phosphatidylethanolamine biosynthetic process, choline binding, CDP-choline pathway
InterPro Term DUF227, Aminoglycoside_PTrfase, Choline/ethanolamine_kinase
UniProt Accession P35790, E9PM06
Search EB-eye ENSG00000110721
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
MCF7
2
E-MTAB-37, E-GEOD-5258
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC2157
2
E-MTAB-37, E-MTAB-62
HT1080
2
E-MTAB-37, E-GEOD-20089
449 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (54 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-3204
testis - germ cell
2
E-AFMX-5, E-TABM-145
PBMCs
1
E-GEOD-20677
lymphocyte
1
E-GEOD-11755
mesenchymal stem cell
1
E-GEOD-9894
BDCA1+ dendritic cell
1
1
E-TABM-34
98 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-2280, E-GEOD-16363, ... (56 experiments)

Factor Value U/D Experiments
ischemic cardiomyopathy
2
E-GEOD-1869, E-GEOD-1145
colon carcinoma
2
E-MTAB-37, E-MTAB-62
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
colorectal adenocarcinoma
2
E-AFMX-5, E-MTAB-62
control
2
E-GEOD-21912, E-GEOD-16363
197 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (27 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-5824, E-GEOD-6907, E-GEOD-412, E-TABM-868, E-MEXP-1958, ... (10 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
bacterial endotoxin
1
E-GEOD-3284
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
unknown
1
E-GEOD-7307
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-16363, E-MEXP-935, E-GEOD-3004, ... (28 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.316 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM